Nine Covid symptoms affecting the fully vaccinated — and signs you may have it Fainting and fatigue may signal onset of variant, experts say The Independent UK · Nov 3, 2022
Ketamine ‘saved my life’: Depressed, anxious Floridians turn to unregulated psychadelics ORLANDO, Fla. — Ashley Blanco, 27, has grappled with anxiety, depression and obsessive-compulsive disorder for the better part of a decade. Antidepressants and therapy didn’t help. After she graduated college, the COVID-19 pandemic hit. It sent her mental health to an all-time low. Orlando Sentinel · Nov 3, 2022
US pharmacies announce opioid settlements totaling $10 billion The two largest US pharmacy chains, CVS Health and Walgreen Co., announced agreements in principle on Wednesday to pay about $5 billion each to settle lawsuits nationwide over the toll of opioids, and a lawyer said Walmart, a third pharmacy behemoth, is in discussions for a deal. France 24 · Nov 2, 2022
Tory MP previously flagged for outside jobs made Health Select Committee chair A TORY MP who was flagged by a lobbying watchdog over external jobs with pharma companies has been made the chair of the Health Select Committee. The National (Scotland) · Nov 2, 2022
Almost two-thirds of Australians — including children — have had COVID-19, blood study suggests Research suggesting almost two-thirds of Australians have had COVID-19 comes via blood studies from the National Centre for Immunisation Research and Surveillance. ABC News · Nov 2, 2022
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing. Benzinga · Nov 2, 2022
US pharmacy companies reach $10bn settlement over opioid claims The deals mean CVS and Walgreens will pay more than $10bn for their roles in the US opioid crisis. Al Jazeera · Nov 2, 2022
CVS, Walgreens announce opioid settlements totaling $10 billion CVS and Walgreens have agreed in principle to pay a total of about $10 billion to settle lawsuits over the toll of powerful prescription opioids. Chicago Sun-Times · Nov 2, 2022
New Tory Health Committee chair was rapped by lobbying watchdog over pharma job The Mirror revealed in January that ex-health minister Steve Brine made £200-an-hour giving 'strategic advice' to drug firm Sigma without first checking with the Advisory Body on Business Appointments (ACOBA) Daily Mirror · Nov 2, 2022
Uganda's Ebola responders fret as some people fight measures Ugandan health officials say they have controlled the spread of a strain of Ebola that has no proven vaccine, But there are pockets of resistance to health measures in rural communities where illiteracy is high and restrictions on movement and business activity have left many bitter The Independent UK · Nov 2, 2022
CVS and Walgreens announce opioid settlements totaling $10 billion It could amount to the last round of huge settlements after years of litigation over the industry's role in an overdose crisis linked to more than 500,000 deaths in the U.S. over the past two decades. WEKU · Nov 2, 2022
CVS, Walgreens reach $5 billion deals to settle opioid lawsuits They are the two largest drugstore chains in the U.S. Axios · Nov 2, 2022
How long can you test positive for Covid and when are you infectious? A surge in cases is indicating a new wave has started in the UK The Independent UK · Nov 2, 2022
Nine Covid symptoms affecting the fully vaccinated — and signs you may have it Fainting and fatigue may signal onset of variant, experts say The Independent UK · Nov 2, 2022
Asharq Al-Awsat · Nov 2, 2022 Estee Lauder Cuts Annual Forecasts as China Curbs Drag Demand Estee Lauder Cos Inc cut its full-year sales and profit forecasts on Wednesday, signaling a hit to sales from persistent COVID-19-related lockdowns and store closures in major market China. The New York-based company's shares were down about 5% in premarket trade. Sales growth of many US companies like Estee has…
The Independent UK · Nov 2, 2022 Who can get an autumn Covid booster jab and how do I book? Booster vaccinations are being offered to everyone in England over the age of 50
The Independent UK · Nov 2, 2022 CVS Health agrees to $5B settlement of opioid lawsuits CVS Health says it has agreed to pay about $5 billion to state, local and Native American tribal governments to settle lawsuits over the toll of opioids
ABC News · Nov 2, 2022 The WHO says monkeypox is still a global health emergency of concern, despite a 'promising' decline in cases Despite a promising decline in global cases, the World Health Organization has determined that monkeypox should remain a "public health emergency of international concern". Here's why.
Axios · Nov 2, 2022 The health care cost wars may be coming to a head If they do, the political fallout will be defined by industry group brawling.
Pedestrian.tv · Nov 2, 2022 A Multi-National Mega Corp Trialled The 4-Day Work Week Got Great Results So Let’s Goooo If even Unilever, of all companies, is allowing its staff a 4 day work week then we know that shit works.
AAP · Nov 2, 2022 CSL paying $312m to license mRNA vax tech CSL Seqirus is paying $A312 million up-front to license next-generation mRNA technology from a small US company, Arcturus Therapeutics.
Benzinga · Nov 1, 2022 Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.
Benzinga · Nov 1, 2022 Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)
Benzinga · Nov 1, 2022 Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
StockNews.com · Nov 1, 2022 The Worst Biotech Stocks Investors Could Buy This Fall Timber Pharmaceuticals (TMBR) recently received an NYSE warning for not meeting the minimum trading price requirement for quite some time. The stock has lost 84% year-to-date. Given the company’s weak fundamentals, the stock could be a poor choice for investors enticed by its negligible price. Let’s discuss….